By Katherine Ellen Foley and Megan Wilson

The agency made a few tweaks, but mostly sticks to its proposed coverage plan despite outrage from drug companies and patient advocates.

The agency made a few tweaks, but mostly sticks to its proposed coverage plan despite outrage from drug companies and patient advocates.

The agency made a few tweaks, but mostly sticks to its proposed coverage plan despite outrage from drug companies and patient advocates.

The agency made a few tweaks, but mostly sticks to its proposed coverage plan despite outrage from drug companies and patient advocates.

Their goal is to strong arm the Centers for Medicare and Medicaid Services into covering Aduhelm, the $28,200-per-year drug, for far more people.

Their goal is to strong arm the Centers for Medicare and Medicaid Services into covering Aduhelm, the $28,200-per-year drug, for far more people.